CLDN3 and non-small cell lung carcinoma: YM201636, a PIKfyve inhibitor, demonstrates dose-dependent suppression of NSCLC cell proliferation with cell-type–specific claudin modulation (upregulating CLDN1/3/5 in HCC827, CLDN3/5 in Calu-1, and CLDN5 with CLDN1 reduction in H1299) and consistent epidermal growth factor receptor (EGFR) mRNA induction, suggesting PIKfyve-EGFR crosstalk in EGFR-activated NSCLC (49).